Richard W Joseph Jr. MD
Genitourinary Oncology, Hematologic Oncology, Melanoma
Executive Medical Director Menarini Stemline
Join to View Full Profile
4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000
Fax+1 888-978-4098
Dr. Joseph is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a medical oncologist working in Drug Development for Daiichi Sankyo.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
Emory University School of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2006 - Present
FL State Medical License 2011 - 2027
TX State Medical License 2007 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Powerchart, Cerner Healthe and IQHealth, Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification FirstNet (Clinical), Cerner Corporation, 2013-2015, 2017
Clinical Trials
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma Start of enrollment: 2014 Jan 08
- Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
- A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) Start of enrollment: 2014 May 31
Publications & Presentations
PubMed
- 20 citationsA Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong
Journal of Thoracic Oncology. 2025-11-01 - 36 citationsEfficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carc...Thomas Powles, Michael B. Atkins, Bernard Escudier, Robert J. Motzer, Brian I. Rini
European Urology. 2021-05-01 - 4 citationsIdentifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.Patricia LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John D. Carpten
Plos One. 2021-04-07
Journal Articles
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell CarcinomaMichael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Lectures
- Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings.2019 ASCO Annual Meeting - 6/1/2019
- Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Pembrolizumab May Help Prevent Early-Stage Melanoma from ReturningOctober 13th, 2021
Presents State of the Science Summit™ on Genitourinary CancersJuly 23rd, 2019
Immunotherapy Highly Effective in Treatment of Rare Skin Cancer, Study FindsJanuary 10th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
